

Cited In for PMID: 27390158

299 results

<< < Page 1 of 30 > >>

- 1 **225Ac-PSMA-617 for PSMA-Targeted α -Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.**
 Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, Kopka K, Apostolidis C, Haberkorn U, Morgenstern A.
 J Nucl Med. 2016 Dec;57(12):1941-1944. doi: 10.2967/jnumed.116.178673. Epub 2016 Jul 7.
 PMID: 27390158 [Free article.](#)
- 2 **GAD1 contributes to the progression and drug resistance in castration resistant prostate cancer.**
 Wan L, Liu Y, Liu R, Mao W.
 Cancer Cell Int. 2023 Oct 30;23(1):255. doi: 10.1186/s12935-023-03093-4.
 PMID: 37904122 [Free PMC article.](#)
- 3 **Initial Findings on the Use of [^{225}Ac]Ac-DOTATATE Therapy as a Theranostic Application in Patients with Neuroendocrine Tumors.**
 Demirci E, Alan Selçuk N, Beydağı G, Ocak M, Toklu T, Akçay K, Kabasakal L.
 Mol Imaging Radionucl Ther. 2023 Oct 20;32(3):226-232. doi: 10.4274/mirt.galenos.2023.38258.
 PMID: 37870290 [Free PMC article.](#)
- 4 **Alpha Particle-Emitting Radiopharmaceuticals as Cancer Therapy: Biological Basis, Current Status, and Future Outlook for Therapeutics Discovery.**
 Coll RP, Bright SJ, Martinus DKJ, Georgiou DK, Sawakuchi GO, Manning HC.
 Mol Imaging Biol. 2023 Oct 16. doi: 10.1007/s11307-023-01857-y. Online ahead of print.
 PMID: 37845582 Review.
- 5 **Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go?**
 Radzina M, Saule L, Mamis E, Koester U, Cocolios TE, Pajuste E, Kalnina M, Palskis K, Sawitzki Z, Talip Z, Jensen M, Duchemin C, Leufgen K, Stora T.
 EJNMMI Radiopharm Chem. 2023 Oct 12;8(1):27. doi: 10.1186/s41181-023-00211-5.
 PMID: 37823964 [Free PMC article.](#) Review.
- 6 **Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy.**
 Abusaleem M, Martiniova L, Soebianto S, DePalatis L, Ravizzini G.
 Cancers (Basel). 2023 Sep 13;15(18):4537. doi: 10.3390/cancers15184537.
 PMID: 37760506 [Free PMC article.](#) Review.
- 7 **[^{225}Ac]Ac- and [^{111}In]In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in vitro and tumour and normal tissue uptake in vivo in NRG mice with HER2-positive human breast cancer xenografts.**
 Kondo M, Cai Z, Chan C, Forkan N, Reilly RM.
 EJNMMI Radiopharm Chem. 2023 Sep 26;8(1):24. doi: 10.1186/s41181-023-00208-0.
 PMID: 37750937 [Free PMC article.](#)
- 8 **Development of [^{225}Ac]Ac-DOTA-C595 as radioimmunotherapy of pancreatic cancer: in vitro evaluation, dosimetric assessment and detector calibration.**
 Hull A, Hsieh W, Borysenko A, Tieu W, Bartholomeusz D, Bezak E.
 EJNMMI Radiopharm Chem. 2023 Sep 7;8(1):22. doi: 10.1186/s41181-023-00209-z.
 PMID: 37679594 [Free PMC article.](#)
- 9 **Lys-urea-Aad, Lys-urea-Cmc and Lys-urea-Cms as potential pharmacophores for the design of PSMA-targeted radioligands to reduce off-target uptake in kidneys and salivary glands.**
 Kuo HT, Zhang Z, Zhang C, Merckens H, Tan R, Wong AAWL, Uribe CF, Bénard F, Lin KS.
 Theranostics. 2023 Aug 15;13(13):4559-4573. doi: 10.7150/thno.87663. eCollection 2023.
 PMID: 37649602 [Free PMC article.](#)

UH & EURATOM Ex. 2029-001**Fusion v. Universität Heidelberg, et al.****IPR2023-00551**

FOLLOW NCBI



Cited In for PMID: 26116124

71 results

Page 1 of 8

- 1 [Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer.](#)
Weineisen M, Simecek J, Schottelius M, Schwaiger M, Wester HJ.
EJNMMI Res. 2014 Dec;4(1):63. doi: 10.1186/s13550-014-0063-1. Epub 2014 Nov 25.
PMID: 26116124 [Free PMC article.](#)
- 2 [\[^{99m}Tc\]Tc-PentixaTec: development, extensive pre-clinical evaluation, and first human experience.](#)
Konrad M, Rinscheid A, Wienand G, Nittbaur B, Wester HJ, Janzen T, Lapa C, Pfob CH, Schottelius M.
Eur J Nucl Med Mol Imaging. 2023 Nov;50(13):3937-3948. doi: 10.1007/s00259-023-06395-x. Epub 2023 Aug 19.
PMID: 37597009 [Free PMC article.](#)
- 3 [N-Alkyl Carbamoylimidazoles as Versatile Synthons for the Synthesis of Urea-Based PSMA Inhibitors.](#)
Gade NR, Kaur J, Bhardwaj A, Ebrahimi E, Dufour J, Wuest M, Wuest F.
ACS Med Chem Lett. 2023 Jun 9;14(7):943-948. doi: 10.1021/acsmchemlett.3c00087. eCollection 2023 Jul 13.
PMID: 37465305
- 4 [Preclinical Evaluation of a PSMA-Targeting Homodimer with an Optimized Linker for Imaging of Prostate Cancer.](#)
Murce E, Beekman S, Spaan E, Handula M, Stuurman D, de Ridder C, Seimbille Y.
Molecules. 2023 May 11;28(10):4022. doi: 10.3390/molecules28104022.
PMID: 37241763 [Free PMC article.](#)
- 5 [Improved quality control of \[¹⁷⁷Lu\]Lu-PSMA I&T.](#)
Kraihammer M, Garnuszek P, Bauman A, Maurin M, Alejandre Lafont M, Haubner R, von Guggenberg E, Gabriel M, Decristoforo C.
EJNMMI Radiopharm Chem. 2023 Mar 27;8(1):7. doi: 10.1186/s41181-023-00191-6.
PMID: 36971890 [Free PMC article.](#)
- 6 [Synthesis and preclinical evaluation of novel ^{99m}Tc-labeled PSMA ligands for radioguided surgery of prostate cancer.](#)
Kunert JP, Müller M, Günther T, Stopper L, Urtz-Urban N, Beck R, Wester HJ.
EJNMMI Res. 2023 Jan 16;13(1):2. doi: 10.1186/s13550-022-00942-7.
PMID: 36645586 [Free PMC article.](#)
- 7 [Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with ¹⁷⁷Lu-PSMA and Combined ²²⁵Ac- and ¹⁷⁷Lu-Labeled PSMA Ligands \(TANDEM-PRLT\) in Advanced Prostate Cancer: A Single-Center Systematic Investigation.](#)
Langbein T, Kulkarni HR, Schuchardt C, Mueller D, Volk GF, Baum RP.
Diagnostics (Basel). 2022 Aug 10;12(8):1926. doi: 10.3390/diagnostics12081926.
PMID: 36010276 [Free PMC article.](#)
- 8 [Reducing the Kidney Uptake of High Contrast CXCR4 PET Imaging Agents via Linker Modifications.](#)
Kwon D, Zhang Z, Zeisler J, Kuo HT, Lin KS, Benard F.
Pharmaceutics. 2022 Jul 20;14(7):1502. doi: 10.3390/pharmaceutics14071502.
PMID: 35890397 [Free PMC article.](#)
- 9 [Production and Quality Control of \[¹⁷⁷Lu\]Lu-PSMA-I&T: Development of an Investigational Medicinal Product Dossier for Clinical Trials.](#)
Di Iorio V, Boschi S, Cuni C, Monti M, Severi S, Paganelli G, Masini C.
Molecules. 2022 Jun 28;27(13):4143. doi: 10.3390/molecules27134143.
PMID: 35807385 [Free PMC article.](#)

FOLLOW NCBI



Connect with NLM

National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894

Web Policies
FOIA
HHS Vulnerability Disclosure
Help
Accessibility
Careers

NLM NIH HHS USA.gov

Cited In for PMID: 26089548

181 results

<< < Page 1 of 19 > >>

1 **68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.**

Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, Kulkarni HR, Lassmann M, Klette I, Eiber M, Schwaiger M, Wester HJ.

J Nucl Med. 2015 Aug;56(8):1169-76. doi: 10.2967/jnumed.115.158550. Epub 2015 Jun 18.

PMID: 26089548 [Free article](#).

2 **Radiometals in Imaging and Therapy: Highlighting Two Decades of Research.**

Sharma S, Pandey MK.

Pharmaceuticals (Basel). 2023 Oct 13;16(10):1460. doi: 10.3390/ph16101460.

PMID: 37895931 [Free PMC article](#). Review.

3 **Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments.**

Le TK, Duong QH, Baylot V, Fargette C, Baboudjian M, Colleaux L, Taïeb D, Rocchi P.

Cancers (Basel). 2023 Oct 19;15(20):5047. doi: 10.3390/cancers15205047.

PMID: 37894414 [Free PMC article](#). Review.

4 **Alpha Particle-Emitting Radiopharmaceuticals as Cancer Therapy: Biological Basis, Current Status, and Future Outlook for Therapeutics Discovery.**

Coll RP, Bright SJ, Martinus DKJ, Georgiou DK, Sawakuchi GO, Manning HC.

Mol Imaging Biol. 2023 Oct 16. doi: 10.1007/s11307-023-01857-y. Online ahead of print.

PMID: 37845582 Review.

5 **Unleashing novel horizons in advanced prostate cancer treatment: investigating the potential of prostate specific membrane antigen-targeted nanomedicine-based combination therapy.**

He M, Cao Y, Chi C, Zhao J, Chong E, Chin KXC, Tan NZV, Dmitry K, Yang G, Yang X, Hu K, Enikeev M.

Front Immunol. 2023 Sep 19;14:1265751. doi: 10.3389/fimmu.2023.1265751. eCollection 2023.

PMID: 37795091 [Free PMC article](#). Review.

6 **Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy.**

Abusaleem M, Martiniova L, Soebianto S, DePalatis L, Ravizzini G.

Cancers (Basel). 2023 Sep 13;15(18):4537. doi: 10.3390/cancers15184537.

PMID: 37760506 [Free PMC article](#). Review.

7 **PSMA Targeted Molecular Imaging and Radioligand Therapy for Prostate Cancer: Optimal Patient and Treatment Issues.**

Hoshi S, Yaginuma K, Meguro S, Onagi A, Matsuoka K, Hata J, Sato Y, Akaihata H, Kataoka M, Ogawa S, Uemura M, Kojima Y.

Curr Oncol. 2023 Aug 1;30(8):7286-7302. doi: 10.3390/curroncol30080529.

PMID: 37623010 [Free PMC article](#). Review.

8 **Improved [⁶⁸Ga]Ga-PSMA-11 image qualities reconstructed by total variation regularized expectation maximization on total-body PET/CT.**

Li L, Chen R, Wen J, Yang X, Hu D, Sun H, Ge Q, Ng YL, Zhou Y, Wan L, Chen Y, Wei W, Liu J.

Quant Imaging Med Surg. 2023 Aug 1;13(8):5230-5241. doi: 10.21037/qims-22-1341. Epub 2023 Jul 11.

PMID: 37581091 [Free PMC article](#).

9 **Synthesis, ¹²³I-Radiolabeling Optimization, and Initial Preclinical Evaluation of Novel Urea-Based PSMA Inhibitors with a Tributylstannyl Prosthetic Group in Their Structures.**

Hasnowo LA, Larkina MS, Plotnikov E, Bodenko V, Yuldasheva F, Stasyuk E, Petrov SA, Zyk NY, Machulkin AE, Vorozhtsov NI, Beloglazkina EK, Nenajdenko VG, Tolmachev V, Orlova A, Majouga AG, Yusubov MS.

Int J Mol Sci. 2023 Jul 30;24(15):12206. doi: 10.3390/ijms241512206.

UH & EURATOM Ex. 2029-005
Fusion v. Universität Heidelberg, et al.
IPR2023-00551

PMID: 37569582 [Free PMC article](#).

10 [The current status of prostate cancer treatment and PSMA theranostics.](#)

Uemura M, Watabe T, Hoshi S, Tanji R, Yaginuma K, Kojima Y.

Ther Adv Med Oncol. 2023 Jul 3;15:17588359231182293. doi: 10.1177/17588359231182293. eCollection 2023.

PMID: 37424944 [Free PMC article](#). Review.

FOLLOW NCBI



Connect with NLM

National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894

- Web Policies
- FOIA
- HHS Vulnerability Disclosure
- Help
- Accessibility
- Careers

NLM NIH HHS USA.gov

Cited In for PMID: 18519789

62 results

<< < Page 1 of 7 > >>

- 1 [Preclinical evaluation of the alpha-particle generator nuclide ²²⁵Ac for somatostatin receptor radiotherapy of neuroendocrine tumors.](#)
 Miederer M, Henriksen G, Alke A, Mossbrugger I, Quintanilla-Martinez L, Senekowitsch-Schmidtke R, Essler M.
 Clin Cancer Res. 2008 Jun 1;14(11):3555-61. doi: 10.1158/1078-0432.CCR-07-4647.
 PMID: 18519789
- 2 [Upregulation of Somatostatin Receptor Type 2 Improves ¹⁷⁷Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model.](#)
 Sharma R, Earla B, Baidoo KE, Zeiger MA, Madigan JP, Escorcía FE, Sadowski SM.
 Mol Cancer Ther. 2023 Sep 5;22(9):1052-1062. doi: 10.1158/1535-7163.MCT-22-0798.
 PMID: 37487000 [Free PMC article.](#)
- 3 [First preclinical evaluation of \[²²⁵Ac\]Ac-DOTA-JR11 and comparison with \[¹⁷⁷Lu\]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs.](#)
 Handula M, Beekman S, Konijnenberg M, Stuurman D, de Ridder C, Bruchertseifer F, Morgenstern A, Denkova A, de Blois E, Seimbille Y.
 EJNMMI Radiopharm Chem. 2023 Jun 30;8(1):13. doi: 10.1186/s41181-023-00197-0.
 PMID: 37389800 [Free PMC article.](#)
- 4 [²²⁵Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic.](#)
 Rubira L, Deshayes E, Santoro L, Kotzki PO, Fersing C.
 Pharmaceutics. 2023 Mar 24;15(4):1051. doi: 10.3390/pharmaceutics15041051.
 PMID: 37111537 [Free PMC article.](#) Review.
- 5 [Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists.](#)
 Shi M, Jakobsson V, Greifenstein L, Khong PL, Chen X, Baum RP, Zhang J.
 Front Med (Lausanne). 2022 Dec 7;9:1034315. doi: 10.3389/fmed.2022.1034315. eCollection 2022.
 PMID: 36569154 [Free PMC article.](#) Review.
- 6 [²²⁵Ac-MACROPATATE: A Novel \$\alpha\$ -Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors.](#)
 King AP, Gutsche NT, Raju N, Fayn S, Baidoo KE, Bell MM, Olkowski CS, Swenson RE, Lin FI, Sadowski SM, Adler SS, Thiele NA, Wilson JJ, Choyke PL, Escorcía FE.
 J Nucl Med. 2023 Apr;64(4):549-554. doi: 10.2967/jnumed.122.264707. Epub 2022 Nov 17.
 PMID: 36396453 [Free PMC article.](#)
- 7 [A Review on Tumor Control Probability \(TCP\) and Preclinical Dosimetry in Targeted Radionuclide Therapy \(TRT\).](#)
 Spoormans K, Crabbé M, Struelens L, De Saint-Hubert M, Koole M.
 Pharmaceutics. 2022 Sep 22;14(10):2007. doi: 10.3390/pharmaceutics14102007.
 PMID: 36297446 [Free PMC article.](#) Review.
- 8 [Gamma counting protocols for the accurate quantification of ²²⁵Ac and ²¹³Bi without the need for a secular equilibrium between parent and gamma-emitting daughter.](#)
 Castillo Seoane D, De Saint-Hubert M, Ahenkorah S, Saldarriaga Vargas C, Ooms M, Struelens L, Koole M.
 EJNMMI Radiopharm Chem. 2022 Oct 23;7(1):28. doi: 10.1186/s41181-022-00174-z.
 PMID: 36274098 [Free PMC article.](#)
- 9 [Refined Chelator Spacer Moieties Ameliorate the Pharmacokinetics of PSMA-617.](#)
 Dos Santos JC, Schäfer M, Bauder-Wüst U, Beijer B, Eder M, Leotta K, Kleist C, Meyer JP, Dilling TR, Lewis JS, Kratochwil C, Kopka K, Haberkorn U, Mier W.
 Front Chem. 2022 Aug 9;10:898692. doi: 10.3389/fchem.2022.898692. eCollection 2022.
 PMID: 36017165 [Free PMC article.](#)

10 [3p-C-NETA: A versatile and effective chelator for development of Al¹⁸F-labeled and therapeutic radiopharmaceuticals.](#)
Ahenkorah S, Murce E, Cawthorne C, Ketchemen JP, Deroose CM, Cardinaels T, Seimbille Y, Fonge H, Gsell W, Bormans G, Ooms M, Cleeren F.
Theranostics. 2022 Aug 8;12(13):5971-5985. doi: 10.7150/thno.75336. eCollection 2022.
PMID: 35966589 [Free PMC article.](#)

FOLLOW NCBI



Connect with NLM

National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894

- Web Policies
- FOIA
- HHS Vulnerability Disclosure
- Help
- Accessibility
- Careers

NLM NIH HHS USA.gov